Novartis Forging Ahead: Exforge Gets Full Approval, To Launch By End Of June
Executive Summary
Novartis will launch its hypertension treatment Exforge by the end of the month following FDA final approval of the product. The drug is the first to combine an angiotensin receptor blocker, Novartis' Diovan (valsartan), with a calcium channel blocker, Pfizer's Norvasc (amlodipine)